Potential Role of Silencing Ribonucleic Acid for Esophageal Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• RNA Therapeutics

Background:

• Esophageal cancer is an aggressive malignancy with high mortality.
• Optimal treatment strategies for esophageal cancer are still under development.
• Ribonucleic acid (RNA) interference offers a novel, targeted therapeutic approach.

Purpose of the Study:

• To explore the potential of RNA interference, specifically small interfering RNA (siRNA), in targeting oncogenes for esophageal cancer treatment.
• To identify key oncogenes and signaling pathways amenable to siRNA-mediated silencing in esophageal cancer.
• To review experimental evidence supporting siRNA's efficacy in inhibiting esophageal cancer progression.

Main Methods:

• A systematic literature search was conducted for articles published between 2005 and August 2020.
• Search terms included "esophageal cancer," "RNA interference," "small interfering RNA (siRNA)," and specific oncogenes/pathways like Hedgehog (Hh), Gli-1, Smoothened (Smo), Bcl-2, STAT3, and Hypoxia inducible factor (HIF).
• A total of 21 relevant articles were analyzed.

Main Results:

• The silencing of specific oncogenes in esophageal cancer cells via siRNA has demonstrated significant effects.
• Observed outcomes include decreased oncogenic protein expression, induction of apoptosis, and reduced cell proliferation.
• Further benefits observed include reduced invasion, migration, epithelial-mesenchymal transition, tumor angiogenesis, metastasis, and overcoming drug resistance.

Conclusions:

• Proto-oncogenes and oncogenes, including Hedgehog (Hh) pathway mediators (Gli-1, Smo), and antiapoptotic proteins (Bcl-2), are viable targets for siRNA-based therapy in esophageal cancer.
• siRNA-mediated gene silencing presents a promising strategy for developing novel treatments for esophageal cancer.
• Experimental findings support the potential clinical application of siRNA in managing esophageal cancer.